[Featured Stock] ABL Bio 'Strong Rise'... Lecanemab Clinical Effect

[Asia Economy Reporter Junho Hwang] ABL Bio is showing strong performance in the stock market on the 29th following news that 'Lecanemab,' a new Alzheimer's treatment candidate developed by Biogen and Eisai, demonstrated efficacy in Phase 3 clinical trials.

As of 9:54 AM, ABL Bio's stock price rose 7.77% from the previous close to 20,750 KRW. This upward trend is attributed to the positive news regarding Lecanemab's clinical trial results.

Seonkyung Lee, a research fellow at IBK Investment & Securities, commented on the potential expansion of ABL Bio's BBB shuttle in relation to the success of Lecanemab's Phase 3 trial, stating, "Lecanemab showed a reduction in plaques and corresponding cognitive improvement effects even in Phase 2 trials, proving that the amyloid hypothesis is still valid."

However, she added, "The issue to consider is that Lecanemab already penetrates the brain well and reduces plaques without using a BBB shuttle, so there may be questions about whether an additional mechanism is necessary." She further explained, "Patients with degenerative brain diseases have damaged BBBs, and the extent varies among patients, so delivery efficiency is needed. Competitors and latecomers will increasingly require BBB shuttles to secure differentiated competitiveness."

This content was produced with the assistance of AI translation services.